Advertisement

Anal Carcinoma Surveillance Counterpoint: Australia

  • Toufic El-KhouryEmail author
  • Michael Solomon
  • Jane Young
Chapter
Part of the Current Clinical Oncology book series (CCO)

Abstract

Surveillance after treatment of anal carcinoma is not as firmly established as surveillance for colorectal cancer. The rarity of the disease means that there is a paucity of data or clinical trials comparing different regimens. The current standard of care for squamous cell carcinoma of the anus consists of combined modality treatment, with a surveillance regimen that aims at detecting recurrent or persistent disease, assessing treatment tolerance and related complications, with salvage surgery being reserved for locoregional failures.

Keywords

Human Papilloma Virus Anal Canal Abdominoperineal Resection Anal Cancer Human Papilloma Virus Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
  2. 2.
    Prestage G, Ferris J, Grierson J, et al. Homosexual men in Australia: population, distribution and HTV prevalence. Sex Health. 2008;5:97–102.PubMedCrossRefGoogle Scholar
  3. 3.
    National Health and Medical Research Council (NHMRC). Clinical practice guidelines for the prevention, early detection and management of colorectal cancer. The Cancer Council Australia, Australian Cancer Network, The Commonwealth of Australia, Canberra; 2005.Google Scholar
  4. 4.
    Fleshner P, Chalasani S, Chang G, et al. Practice parameters for anal squamous neoplasms. Dis Colon Rectum. 2008;51:2–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Young SC, Solomon MJ, Hruby G, Frizelle FA. Review of 120 anal cancer patients. Colorectal Dis. 2009;11:909–14. Epub 2008 Oct 25.PubMedCrossRefGoogle Scholar
  6. 6.
    Christensen A, Nielsen M, Svendsen L, Engelholm S. Three-dimensional anal endosonography may improve detection of recurrent anal cancer. Dis Colon Rectum. 2006;49:1527–32.PubMedCrossRefGoogle Scholar
  7. 7.
    Goldman S, Svensson C, Bronnergard M, Glimelius B, Wallin G. Prognostic significance of serum concentration of squamous cell carcinoma antigen in anal epidermal carcinoma. Ing J Colorectal Dis. 1993;8:98–102.CrossRefGoogle Scholar
  8. 8.
    Petrelli NJ, Palmer M, Herrera L, Bhargava A. The utility of squamous cell carcinoma antigen for the follow-up of patients with squamous cell carcinoma of the anal canal. Cancer. 1992;70:35–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Tasevski R, De Winton E, Ngan S, Mackay J, Hicks R, Heriot A. CR13 utility of 18- fluorodeoxyglucose PET in the staging and management of anal cancer. ANZ J Surg. 2007;77(Suppl sl):A17.CrossRefGoogle Scholar
  10. 10.
    Roohipour R, Patil S, Goodman K, et al. Squamous-cell carcinoma of the anal canal:·predictors of treatment outcome. Dis Colon Rectum. 2008;51:147–53.PubMedCrossRefGoogle Scholar
  11. 11.
    Gervaz P, Hirschel B, Morel P. Molecular biology of squamous cell carcinoma of the anus. Br J Surg. 2006;93:531–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Place R, Gregorcyk S, Huber P, Simmang C. Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. Dis Colon Rectum. 2001;44:506–12.PubMedCrossRefGoogle Scholar
  13. 13.
    Martin F, Bower M. Anal intraepithelial neoplasia in HIV positive people. Sex Transm Infect. 2001;5:327–31.CrossRefGoogle Scholar
  14. 14.
    Hoffinan R, Welton M, Klencke B, Weinberg V, Krieg R. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys. 1999;44:127–31.CrossRefGoogle Scholar
  15. 15.
    Ajani J, Winter K, Gunderson L, et al. Fluorouracil, mitomycin and radiotherapy vs fluorouracil, cisplatin and radiotherapy for carcinoma of the anal canal. JAMA. 2008;299:1914–21.PubMedCrossRefGoogle Scholar
  16. 16.
    Renehan A, Saunders M, Schofield P, O’Dwyer S. Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg. 2005;92:605–14.PubMedCrossRefGoogle Scholar
  17. 17.
    Mariani P, Ghanneme A, De la Rochefordiere A, Girodet J, Falcou M, Salmon R. Abdominoperineal resection for anal cancer. Dis Colon Rectum. 2008;51:1495–501.PubMedCrossRefGoogle Scholar
  18. 18.
    Nilsson PJ, Svenson C, Goldman S, Glimelius B. Salvage abdominoperineal resection in anal epidermoid cancer. Br J Surg. 2002;89:1425–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Ferenschild F, Vermaas M, Hofer SO, Verhoef C, Eggermont A, de Witt JHW. Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer. World J Surg. 2005;29:1452–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Sunesen KG, Buntzen T, Lindegaard J, Norgaard M, Laurberg S. Perineal healing and survival after anal cancer salvage surgery: 10-year experience with primary perineal reconstruction using the vertical rectus abdominis myocutaneous flap. Ann Surg Oncol. 2009;16:68–77. Epub 2008 Nov 5.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press 2013

Authors and Affiliations

  1. 1.Surgical Outcome Research Centre (SOuRCe)Royal Prince Alfred Hospital Sydney and the University of SydneyCamperdownAustralia

Personalised recommendations